Home・Akcijų sąrašas・Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals Inc

Uždarymo kaina

12.52 0.16

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

12.26

Max

12.59

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-4.3M -18M
Pelnas, tenkantis vienai akcijai	-0.19
Darbuotojai	37
EBITDA	-5.3M -17M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+135.06% upside

Dividendai
By Acuity
Kitas uždarbis	2026-11-03

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-21M 1.1B
Ankstesnė atidarymo kaina	12.36
Ankstesnė uždarymo kaina	12.52

Corvus Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-09-18 23:56; UTC

Packaging Corp of America is trading modestly higher in after-market hours, despite unchanged U.S. industrial production and a decline in manufacturing output.

2026-09-18 23:56; UTC

Below 20-day average, near one-month range in after-market hours.

2026-09-18 23:55; UTC

Extreme Networks Inc is trading modestly higher in after-market hours, reflecting typical performance within its one-month range following Friday's close.

2026-09-18 23:55; UTC

Lumen Technologies Inc is trading modestly higher in after-market hours, rebounding from earlier lows amid a broader trend of five consecutive lower daily closes.

2026-09-18 23:55; UTC

Edison International is trading modestly higher in after-market hours, gradually advancing since Friday's close but remains below its 20-day moving average.

2026-09-18 23:52; UTC

Mosaic Co is trading modestly higher in after-hours activity, maintaining a position approximately 1.36% below its 20-day moving average.

2026-09-18 23:52; UTC

Grab Holdings Ltd is trading lower in after-market hours, reaching its lowest price of the day and remaining significantly below its 20-day moving average.

2026-09-18 23:52; UTC

Correlated Moves

Jabil Inc is advancing in after-market trading, reflecting a significant rise since Friday's close and aligning with gains in the iShares Dynamic Equity Active ETF.

2026-09-18 23:52; UTC

Generac Holdings Inc is seeing a modest increase in after-market trading, aligning with broader market trends despite stagnation in U.S. industrial production data for August.

2026-09-18 23:51; UTC

Pacific Biosciences of California Inc declined during after-market trading, moving lower since Friday's close and currently below its 20-day moving average.

2026-09-18 23:51; UTC

Ribbon Communications Inc is declining in after-market trading, moving lower since Friday's close and trading well below its 20-day moving average.

2026-09-18 23:51; UTC

Amphenol Corp is gaining in after-market trading, reaching a notable high since Friday's close, despite remaining below its 20-day moving average.

2026-09-18 23:51; UTC

Lincoln National Corp is trading modestly higher in after-market hours, influenced by broader market gains amid ongoing geopolitical tensions and mixed economic data.

2026-09-18 23:51; UTC

Kyndryl Holdings Inc is moving higher in after-market trading, supported by broader market trends, despite stagnation in U.S. industrial production data for August.

2026-09-18 23:51; UTC

Correlated Moves

Microchip Technology Inc. is trading modestly lower in after-market hours, following a decline from earlier gains amid a broader downturn in the semiconductor sector.

2026-09-18 23:51; UTC

Correlated Moves

Southern Copper Corp is trading modestly lower in after-market hours, continuing a trend observed throughout the day, amid stable performance from the NYLIM FTSE ETF.

2026-09-18 23:51; UTC

EHang Holdings Ltd shows notable strength in after-market trading, advancing significantly from earlier lows despite remaining near the lower end of its one-month trading range.

2026-09-18 23:51; UTC

Cleveland-Cliffs Inc declined in after-market trading but remains above its 20-day moving average and near the upper end of its one-month range.

2026-09-18 23:51; UTC

Charter Communications Inc is rising in after-market trading, reaching its highest cumulative return since Friday's close, reversing a trend of recent declines.

2026-09-18 23:51; UTC

Event

Paychex Inc is trading higher in after-market hours ahead of its Q1 FY2027 earnings report, with EPS estimated at $1.32 and revenue at $1.6 billion.

2026-09-18 23:51; UTC

Devon Energy Corp's shares are modestly higher during after-market hours, currently positioned around the middle of their one-month trading range.

2026-09-18 23:51; UTC

Correlated Moves

Pfizer Inc is trading lower in after-market hours, reflecting a decline since Friday's close, influenced by Bristol-Myers Squibb's recent performance.

2026-09-18 23:51; UTC

American Electric Power Company Inc is trading modestly higher in after-market hours, recovering from earlier lows but remains below its 20-day moving average.

2026-09-18 23:51; UTC

Tractor Supply Co is seeing a modest increase in after-market trading, recovering from an earlier dip amid stagnation in U.S. industrial production.

2026-09-18 23:51; UTC

Kinder Morgan Inc is declining in after-market trading, having reached its lowest point of the day after fluctuating sharply during the session.

2026-09-18 23:46; UTC

Lamb Weston Holdings Inc is trading modestly higher in after-market hours, recovering from a low point shortly after the market closed.

2026-09-18 23:46; UTC

BRC Group Holdings Inc is trading modestly higher in after-market hours, despite a notable decline from earlier gains during the session.

2026-09-18 23:46; UTC

Tripadvisor Inc's stock advanced in after-market trading, fluctuating between a low of 0.06% and a high of 1.19% since Friday's close.

2026-09-18 23:46; UTC

Correlated Moves

Portland General Electric Co is trading modestly higher in after-market hours, reflecting broader gains in the Electric Utilities sector alongside Alliant Energy Corp.

2026-09-18 23:46; UTC

Viavi Solutions Inc is seeing modest gains in after-market trading, recovering from earlier fluctuations that pulled the stock back from a session high.

Akcijų palyginimas

Kainos pokytis

Corvus Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

135.06% į viršų

12 mėnesių prognozė

Vidutinis 29.5 USD 135.06%

Aukščiausias 33 USD

Žemiausias 27 USD

Remiantis 4 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Corvus Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

4 ratings

Pirkti

Laikyti

Parduoti

Remiantis 4 analitikų, pateikusių Corvus Pharmaceuticals Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.